Jiamin Ma

Dr. Jiamin Ma

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

2 January 2026 in Medicine
Verified
Journal Article
Open access
MYMengjie Yang
Mengjie Yang
FZFangyu Zhou
Fangyu Zhou
JMJiamin Ma
Jiamin Ma
WJWenzhong Ji
Wenzhong Ji
NRNingning Ren
Ningning Ren
XRXiaoyi Ren
Xiaoyi Ren
Breast cancer has overtaken lung cancer as the leading malignant tumor affecting women in many countries. Chemotherapy is one of the key adjuvant treatments for breast cancer. Epirubicin and Doxorubicin are the cornerstone of chemotherapy regimens used in clinical practice. This research utilized data extracted from the Food and Drug Administration Adverse Event Reporting System covering the period from the first quarter of 2004 to the third quarter of 2024. We confirmed the findings using the Bayesian confidence propagation neural network. From 2004 Q1 to 2024 Q3, Food and Drug Administration Adverse Event Reporting System contained 12,418,989 adverse event reports, with 5732 linked to Epirubicin and 30,613 to Doxorubicin. Febrile neutropenia (Epirubicin: 95% CI lower bound = 10.03, IC-2SD = 3.23; Doxorubicin: 95% CI lower bound = 32.68, IC-2SD = 4.89), cardiotoxicity (Epirubicin: 95% CI lower bound = 22.41, IC-2SD = 3.99; Doxorubicin: 95% CI lower bound = 62.02, IC-2SD = 5.68) exhibited a strong association with both Epirubicin and Doxorubicin. Epirubicin was more prone to the following adverse reactions: granulocyte count decreased (Epirubicin: χ 2 = 1092.8, 95% CI lower bound = 34.48, IC-2SD = 3.4). Doxorubicin was more prone to the following adverse reactions: hepatitis b reactivation (Doxorubicin: χ 2 = 7899.99, 95% CI lower bound = 39.17, IC-2SD = 4.91). Epirubicin was mainly associated with hematological, cardiac, and hepatobiliary adverse events, while Doxorubicin showed a broader spectrum, including neoplastic disorders and infections. Based on the above differences, the clinical drug selection should be balanced by the patient’s hematological status, cardiac function and HBV carrier/infection risk.

28 February 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
JMJiamin Ma
Jiamin Ma
YZYuanyuan Zhai
Yuanyuan Zhai
XRXiaoyi Ren
Xiaoyi Ren
HWHuifang Wu
Huifang Wu
MYMengjie Yang
Mengjie Yang
JCJianzhong Chen
Jianzhong Chen
Breast cancer remains one of the foremost global health concerns, highlighting the urgent need for innovative diagnostic and therapeutic strategies. Traditional imaging techniques, such as mammography and ultrasound, play essential roles in clinical practice; however, they often fall short in detecting early-stage tumors and providing comprehensive insights into the mechanical properties of cancer cells. In this context, Atomic Force Microscopy (AFM) has emerged as a transformative tool in breast cancer research, owing to its high-resolution imaging capabilities and nanomechanical characterization. This review explores recent advancements in AFM technology as applied to breast cancer research, emphasizing key findings that include the differentiation of various stages of tumor progression through high-resolution imaging, precise characterization of mechanical properties, and the capability for single-cell analysis. These capabilities not only enhance our understanding of tumor heterogeneity but also reveal potential biomarkers for early detection and therapeutic targets. Furthermore, the review critically examines several challenges and limitations associated with the application of AFM in breast cancer research. Issues such as complexities in sample preparation, accessibility, and the cost of AFM technology are discussed. Despite these challenges, the potential of AFM to transform our understanding of breast cancer biology is significant. Looking ahead, continued advancements in AFM technology promise to deepen our insights into breast cancer biology and guide innovative therapeutic strategies aimed at improving patient outcomes.

3 April 2026 in Medicine
Verified
Journal Article
Open access
FZFangyu Zhou
Fangyu Zhou
MYMengjie Yang
Mengjie Yang
WJWenzhong Ji
Wenzhong Ji
JMJiamin Ma
Jiamin Ma
NRNingning Ren
Ningning Ren
XRXiaoyi Ren
Xiaoyi Ren
Leuprolide and Goserelin, both gonadotropin-releasing hormone (GnRH) agonists, are commonly used for ovarian function suppression and the management of hormone-dependent cancers. However, systematic comparisons of their adverse event (AE) profiles based on real-world pharmacovigilance data remains limited. This study aimed to compare the safety signals associated with Leuprolide and Goserelin using the the U.S. Food and Drug Administration AE Reporting System (FAERS), thereby providing insights into their distinct AE patterns. Food and Drug Administration Adverse Event Reporting System reports from the first quarter of 2004 to the third quarter of 2024 were extracted and standardized. Disproportionality signal detection was performed using the reporting odds ratio, proportional reporting ratio, chi-square (χ 2 ) test, and Bayesian confidence propagation neural network. Significant signals were defined as reporting odds ratio lower 95% CI >1, proportional reporting ratio ≥2 with χ 2 ≥4, or Bayesian confidence propagation neural network information component (IC)-2SD >0. Key signals were compared between Leuprolide- and Goserelin-related reports. A total of 12,418,989 AE reports were identified, including 64,324 Leuprolide-related and 4253 Goserelin-related cases. Both drugs showed strong signals for “prostatic specific antigen increased” (Leuprolide: χ 2 = 84,009.65, IC-2SD = 5.42; Goserelin: χ 2 = 820.31, IC-2SD = 3.38), “blood testosterone increased” (Leuprolide: χ 2 = 22,845.52, IC-2SD = 5.56; Goserelin: χ 2 = 290.23, IC-2SD = 2.28), and “prostatic specific antigen abnormal” (Leuprolide: χ 2 = 51,615.98, IC-2SD = 6.46; Goserelin: χ 2 = 422.43, IC-2SD = 2.16). Additional strong signals, such as “prostate cancer metastatic” and “hot flush,” were consistently detected in both groups. Notably, the distribution of AEs differed between drugs, suggesting drug-specific safety patterns. Leuprolide demonstrated strong associations with AEs in “Reproductive system and breast disorders,” “Neoplastic benign and malignant conditions,” and procedure-related categories, whereas Goserelin was more strongly linked to “Endocrine disorders.” These findings highlight distinct pharmacovigilance profiles between the 2 drugs and provide clinically relevant evidence to support individualized risk monitoring in hormone-dependent cancer therapies.

21 August 2026 in Medicine
Verified
Journal Article
Open access
NRNingning Ren
Ningning Ren
MYMengjie Yang
Mengjie Yang
FZFangyu Zhou
Fangyu Zhou
JMJiamin Ma
Jiamin Ma
WJWenzhong Ji
Wenzhong Ji
XRXiaoyi Ren
Xiaoyi Ren
Sex steroid hormones, including estradiol (E2), estrone (E1), follicle-stimulating hormone (FSH), and luteinizing hormone (LH), have been implicated in the development of female malignancies (FMs), yet their independent and combined effects remain unclear. We conducted a cross-sectional analysis using data from the National Health and Nutrition Examination Survey (NHANES). Weighted logistic regression, restricted cubic spline modeling, and chi-square trend tests were applied to evaluate dose-response associations. Machine learning algorithms, including Bayesian Kernel Machine Regression, Extreme Gradient Boosting, Shapley Additive Explanations, Least Absolute Shrinkage and Selection Operator regression, and Random Forest, were used to explore nonlinear relationships and assess variable importance in an exploratory manner. Sensitivity analyses confirmed the robustness of the findings. A total of 2108 participants were included. Higher FSH and LH levels were associated with increased odds of FMs, whereas higher E2 levels were associated with lower odds. In exploratory machine learning analyses, FSH and E1 were consistently ranked as important predictors of FMs. In this cross-sectional analysis, LH and FSH were associated with increased odds of FM, while higher E2 levels were inversely associated with malignancy risk. Exploratory machine learning analyses highlighted additional nonlinear patterns involving E2 and E1.